Reaction

Empyema reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,968 reports · 68 co-occurring drugs

As of the last recalculation, Empyema appears in 1,968 FAERS reports alongside 68 co-occurring drug terms. The strongest observed disproportionality signal is ACETYLCYSTEINE (PRR 49.3).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Acetylcysteine	43	49.3	49.5
Cefazolin	18	21.1	21.1
Micafungin Sodium	15	18.8	18.9
Cefazolin Sodium	18	15.9	16.0
Piperacillin And Tazobactam	17	14.2	14.2
Basiliximab	15	13.6	13.6
Ceftriaxone	39	12.8	12.8
Methylprednisolone	147	12.1	12.1
Bortezomib	94	11.6	11.6
Piperacillin Sodium And Tazobactam Sodium	21	11.4	11.4
Piperacillin Sodium,Tazobactam Sodium	28	11.3	11.3
Thiotepa	10	11.1	11.1
Vancomycin	59	11.1	11.1
Ceftriaxone Sodium	39	11.0	11.0
Vancomycin Hydrochloride	66	10.9	10.9
Voriconazole Injection	22	10.8	10.8
Oseltamivir	8	10.7	10.7
Polyethylene Glycol	10	9.8	9.8
Mycophenilic Acid	18	9.3	9.3
Voriconazole	26	9.2	9.2
Cisplatin	65	9.1	9.1
Amoxicillin And Clavulanate Potassium	21	8.2	8.3
Tacrolimus Ointment 0.1%	93	8.2	8.2
Bleomycin Sulfate	8	8.2	8.2
Tacrolimus Extended-Release Capsules	93	8.2	8.2
Gentamicin	10	8.1	8.1
Gentamicin Sulfate	12	8.1	8.1
Remdesivir	10	8.0	8.0
Linezolid	22	7.9	7.9
Mycophenolate Mofetil	96	7.8	7.8
Mycophenolate Mofetil Hydrochloride	96	7.8	7.8
Alteplase	11	7.8	7.8
Rituximab	145	7.8	7.8
Baricitinib	7	7.7	7.7
Meropenem	23	7.7	7.7
Cefepime	10	7.4	7.4
Cefepime Hydrochloride	11	7.3	7.3
Tacrolimus	102	7.2	7.2
Prochlorperazine Maleate	6	6.9	6.9
Cyclophosphamide Injection, Solution	110	6.9	6.9
Cyclophosphamide	110	6.9	6.9
Cyclophosphamide For Injection	110	6.9	6.9
Atovaquone	5	6.6	6.6
Paclitaxel (Aibumin-Bound)	50	6.6	6.6
Pemetrexed	13	6.4	6.5
Clozapine	72	6.3	6.3
Carboplatin	70	6.0	6.0
Dornase Alfa	11	6.0	6.0
Valacyclovir	23	5.9	5.9
Paclitaxel	53	5.8	5.8
Bupivacaine	5	5.7	5.7
Sorafenib	10	5.1	5.1
Iohexol	4	5.1	5.1
Budesonide, Glycopyrrolate, And Formoterol Fumarate	5	5.1	5.1
Gefitinib	4	4.7	4.7
Pemetrexed Disodium	16	4.5	4.5
Durvalumab	8	4.2	4.2
Crizotinib	5	4.2	4.2
Ipilimumab	16	3.9	3.9
Canakinumab	4	3.9	3.9
Nivolumab	35	3.9	3.9
Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride And Dextrose	3	3.9	3.9
Atezolizumab	13	3.6	3.6
Romiplostim	5	3.5	3.5
Dasatinib	12	3.4	3.4
Axicabtagene Ciloleucel	3	3.2	3.2
Benralizumab	6	3.2	3.2
Osimertinib	6	2.0	2.0

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.